Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET/MRI Imaging
- Registration Number
- NCT06568783
- Lead Sponsor
- Farshad Moradi
- Brief Summary
This study proposes the use of a PET isotope, \[18F\]-Fibroblast Activation Protein Inhibitor-74, for a prospective single-center, single-arm study using MRI imaging for participants with Refractory Dermatomyostitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
- Patients with suspected dermatomyositis.
- Patient must be > 18 years old.
- Be willing and able to provide written informed consent for the trial.
Exclusion Criteria
- Women who are pregnant or potentially pregnant per the Department of Radiology Policy on Imaging in Potentially Pregnant and Pregnant Women.
- Contraindication to MRI or inability to lie flat for 30 min
- Any serious medical condition that in the opinion of principal investigator could pose significant risk of harm or injury to the patient if they participate in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description [18F]-FAPI-74 PET/ MRI [18F]-FAPI-74 Participant receive \[18F\]-FAPI-74 injection and approximately 45-60 minutes later receive a MRI scan from vertex to legs, followed by a static PET emission scan over the same area.
- Primary Outcome Measures
Name Time Method Rate of [18F]-FAPI-74 uptake. up to 1 hour write the outcome title, how it will be measured.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Stanford University
🇺🇸Stanford, California, United States
Stanford University🇺🇸Stanford, California, United States